191 related articles for article (PubMed ID: 37158585)
1. Impact of Vedolizumab on Extraintestinal Manifestations in Inflammatory Bowel Disease: Results From a Descriptive, Retrospective, Real-world Study.
Kopylov U; Burisch J; Ben-Horin S; Braegger F; Fernández-Nistal A; Lara N; Heinrich HS; Vavricka SR
Inflamm Bowel Dis; 2023 Nov; 29(11):1713-1722. PubMed ID: 37158585
[TBL] [Abstract][Full Text] [Related]
2. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.
Fleisher M; Marsal J; Lee SD; Frado LE; Parian A; Korelitz BI; Feagan BG
Dig Dis Sci; 2018 Apr; 63(4):825-833. PubMed ID: 29484571
[TBL] [Abstract][Full Text] [Related]
3. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.
Tadbiri S; Peyrin-Biroulet L; Serrero M; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Gilletta C; Gagniere C; Vuitton L; Viennot S; Aubourg A; Pelletier AL; Bouguen G; Abitbol V; Fumery M; Claudepierre P; Bouhnik Y; Amiot A;
Aliment Pharmacol Ther; 2018 Feb; 47(4):485-493. PubMed ID: 29250803
[TBL] [Abstract][Full Text] [Related]
4. Vedolizumab-Induced De Novo Extraintestinal Manifestations.
Diaz LI; Keihanian T; Schwartz I; Bin Kim S; Calmet F; Alejandra Quintero M; Abreu MT
Gastroenterol Hepatol (N Y); 2020 Feb; 16(2):75-81. PubMed ID: 34035705
[No Abstract] [Full Text] [Related]
5. The impact of vedolizumab therapy on extraintestinal manifestations in patients with inflammatory bowel disease: A systematic review and meta-analysis.
Zheng DY; Wang YN; Huang YH; Jiang M; Ma YN; Dai C
J Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38740543
[TBL] [Abstract][Full Text] [Related]
6. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
Dubinsky MC; Cross RK; Sandborn WJ; Long M; Song X; Shi N; Ding Y; Eichner S; Pappalardo B; Ganguli A; Wang A
Inflamm Bowel Dis; 2018 Aug; 24(9):1876-1882. PubMed ID: 29668916
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study.
Ramos GP; Dimopoulos C; McDonald NM; Janssens LP; Hung KW; Proctor D; Ruggiero E; Kane S; Bruining DH; Faubion WA; Raffals LE; Loftus EV; Al-Bawardy B
Inflamm Bowel Dis; 2021 Jul; 27(8):1270-1276. PubMed ID: 33165569
[TBL] [Abstract][Full Text] [Related]
8. The impact of colectomy on the course of extraintestinal manifestations in Swiss inflammatory bowel disease cohort study patients.
Roth R; Vavricka S; Scharl M; Schreiner P; Safroneeva E; Greuter T; Zeitz J; Misselwitz B; Schoepfer A; Barry MP; Rogler G; Biedermann L;
United European Gastroenterol J; 2021 Sep; 9(7):773-780. PubMed ID: 34431613
[TBL] [Abstract][Full Text] [Related]
9. Clinical Features Focusing on Extraintestinal Manifestations in Japanese Patients with Inflammatory Bowel Diseases: Far East 1000.
Ohta Y; Taida T; Kato J; Ogasawara S; Oyama Y; Mamiya Y; Nakazawa H; Horio R; Goto C; Takahashi S; Kurosugi A; Sonoda M; Shiratori W; Kaneko T; Yokoyama Y; Akizue N; Ishigami H; Koseki H; Okimoto K; Saito K; Saito M; Matsumura T; Nakagawa T; Masuya Y; Fukuda Y; Kitsukawa Y; Shimura H; Tsuyuguchi T; Kato N
Digestion; 2023; 104(4):328-334. PubMed ID: 36893744
[TBL] [Abstract][Full Text] [Related]
10. The Risk of Later Diagnosis of Inflammatory Bowel Disease in Patients With Dermatological Disorders Associated With Inflammatory Bowel Disease.
King D; Chandan JS; Thomas T; Nirantharakumar K; Reulen RC; Adderley NJ; Trudgill N
Inflamm Bowel Dis; 2021 Oct; 27(11):1731-1739. PubMed ID: 34669933
[TBL] [Abstract][Full Text] [Related]
11. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
[TBL] [Abstract][Full Text] [Related]
12. Characterization and prevalence of extraintestinal manifestations in a cohort of patients with inflammatory intestinal disease in Medellin, Colombia.
Juliao-Baños F; Arrubla M; Osorio L; Camargo J; Londoño J; Cáceres C; Carvajal J; Mosquera-Klinger G; Donado J
Gastroenterol Hepatol; 2021; 44(6):398-404. PubMed ID: 33172691
[TBL] [Abstract][Full Text] [Related]
13. Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab.
Dupré A; Collins M; Nocturne G; Carbonnel F; Mariette X; Seror R
Rheumatology (Oxford); 2020 Nov; 59(11):3275-3283. PubMed ID: 32259251
[TBL] [Abstract][Full Text] [Related]
14. Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience.
Erdoğan Ç; Yeşil B; Bacaksız F; Arı D; Gökbulut V; Yüksel M; Özderin Özin Y; Kayaçetin E
Turk J Gastroenterol; 2022 Oct; 33(10):831-837. PubMed ID: 35946879
[TBL] [Abstract][Full Text] [Related]
15. Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.
Hanzel J; Ma C; Casteele NV; Khanna R; Jairath V; Feagan BG
Drugs; 2021 Feb; 81(3):333-347. PubMed ID: 33400241
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous manifestations of inflammatory bowel disease: basic characteristics, therapy, and potential pathophysiological associations.
He R; Zhao S; Cui M; Chen Y; Ma J; Li J; Wang X
Front Immunol; 2023; 14():1234535. PubMed ID: 37954590
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and predictors of arthralgia after initiation of vedolizumab in patients with inflammatory bowel disease: a retrospective cohort study.
Kokkotis G; Zampeli E; Tzouvala M; Giotis I; Orfanos P; Benetou V; Stoupaki M; Leontidis N; Leonidakis G; Kitsou V; Gaki A; Lagiou P; Michopoulos S; Bamias G
Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):371-375. PubMed ID: 36827531
[TBL] [Abstract][Full Text] [Related]
18. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials.
Feagan BG; Sandborn WJ; Colombel JF; Byrne SO; Khalid JM; Kempf C; Geransar P; Bhayat F; Rubin DT
J Crohns Colitis; 2019 Jan; 13(1):50-57. PubMed ID: 30203005
[TBL] [Abstract][Full Text] [Related]
19. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study.
Atia O; Shavit-Brunschwig Z; Mould DR; Stein R; Matar M; Aloi M; Ledder O; Focht G; Urlep D; Hyams J; Broide E; Weiss B; Levine J; Russell RK; Turner D
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):31-42. PubMed ID: 36306803
[TBL] [Abstract][Full Text] [Related]
20. Severe Disease Activity Based on the Paris Classification Is Associated with the Development of Extraintestinal Manifestations in Korean Children and Adolescents with Ulcerative Colitis.
Jang HJ; Suh HR; Choi S; Hong SJ; Cho SM; Choi KH; Choe BH; Kang B;
J Korean Med Sci; 2021 Nov; 36(44):e278. PubMed ID: 34783212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
